Please login to the form below

Not currently logged in
Email:
Password:

Metrion Biosciences adds to its board

Dr Barry Kenny and Dr Andrew Southan join the company

Metrion Biosciences, the specialist ion channel contract research and drug discovery group, has appointed Dr Barry Kenny and Dr Andrew Southan to its board of directors, a move that will see the group strengthen the company’s focus on commercial and business development capabilities.

Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

He has held roles for Paradigm Therapeutics and Pfizer.

Dr Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017.

He has over 25 years’ experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.

Dr Keith McCullagh, non-executive chairman of Metrion Biosciences, said: “I am delighted to welcome both Barry and Andy to Metrion’s board of directors.

“Barry’s substantial experience of drug discovery deal-making will be of great value to Metrion as we continue to build our worldwide CRO and collaboration business, and Andy’s dedication to Metrion’s client service and quality of operations has been a major factor of growth of the business.”

20th March 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics